Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
4(31%)
Results Posted
25%(1 trials)

Phase Distribution

Ph phase_3
3
23%
Ph phase_1
1
8%
Ph phase_2
1
8%
Ph early_phase_1
3
23%
Ph not_applicable
4
31%
Ph phase_4
1
8%

Phase Distribution

4

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution13 total trials
Early Phase 1First-in-human
3(23.1%)
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
1(7.7%)
Phase 3Large-scale testing
3(23.1%)
Phase 4Post-market surveillance
1(7.7%)
N/ANon-phased studies
4(30.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

13

all time

Status Distribution
Active(4)
Completed(4)
Terminated(1)
Other(4)

Detailed Status

Completed4
unknown4
Recruiting3
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (23.1%)
Phase 11 (7.7%)
Phase 21 (7.7%)
Phase 33 (23.1%)
Phase 41 (7.7%)
N/A4 (30.8%)

Trials by Status

withdrawn18%
recruiting323%
active_not_recruiting18%
completed431%
unknown431%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13